Real-world data provide information about the efficacy and safety of rFIX products in everyday clinical practice.
Patients With Hemophilia B Receiving SHL rFIX
Data derived from a health record-based survey of European and US haematologists (n=150 patients with hemophilia B, 114 of whom were taking SHL rFIX). Overall, 67% of the overall group were on prophylactic rFIX, the remainder received on-demand treatment. Information is not available on the proportion of patients receiving on-demand rFIX treatment. n/N: n, number of patients with no missed doses in the last 10 doses; N, patients with physician-reported dose data.
No head-to-head trials comparing the efficacy of EHL versus SHL factor replacement products have been reported. The available real-world data are of small sample size, particularly for the FIX EHL groups. Therefore, these data are subject to biases and other limitations (e.g. recall and selection biases, retrospective non-randomised cross-sectional study, small sample size (particularly for the EHL group) and lack of data adjustment for treatment regimens).
Patients With Hemophilia B Receiving EHL rFIX
Data derived from a health-record based survey of European and US haematologists (n=150 patients with hemophilia B, 36 of whom were taking EHL rFIX). Overall, 67% of the overall group were on prophylactic rFIX, the remainder received on-demand treatment. Information is not available on the proportion of patients receiving on-demand rFIX treatment. n/N: n, number of patients with no missed doses in the last 10 doses; N, patients with physician-reported dose data.
ABR, annualised bleed rate; EHL, extended half-life; FIX, factor IX; rFIX, recombinant factor IX; SHL, standard half-life.
PP-BEN-IND-0038 June 2023
See how BeneFIX® performs in real-life settings.
Review real-world data
BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works
Learn more
BeneFIX® provides dosing options based on individual needs
Learn more
See how BeneFIX® performs in real-life settings.
Review real-world data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.